Evidence map›Paper›PMID 40875531›Full record

ArticleJCI insight2025

Development and preclinical evaluation of next-generation ΔsigH-based live candidate vaccines.

Garima Arora, Caden W Munson, Mushtaq Ahmed, Vinay Shivanna, Annu Devi, Venkata Sr Devireddy, Basil Antony, Shannan Hall-Ursone, Olga D Gonzalez, Edward J Dick and 6 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Garima AroraTexas Biomedical Research Institute, San Antonio, Texas, USA.
Caden W MunsonTexas Biomedical Research Institute, San Antonio, Texas, USA.
Mushtaq AhmedDepartment of Microbiology, University of Chicago, Chicago, Illinois, USA.
Vinay ShivannaTexas Biomedical Research Institute, San Antonio, Texas, USA.
Annu DeviTexas Biomedical Research Institute, San Antonio, Texas, USA.
Venkata Sr DevireddyTexas Biomedical Research Institute, San Antonio, Texas, USA.
Basil AntonyTexas Biomedical Research Institute, San Antonio, Texas, USA.
Shannan Hall-UrsoneTexas Biomedical Research Institute, San Antonio, Texas, USA.
Olga D GonzalezTexas Biomedical Research Institute, San Antonio, Texas, USA.
Edward J DickTexas Biomedical Research Institute, San Antonio, Texas, USA.
Chinnaswamy JagannathHouston Methodist Research Institute, Houston, Texas, USA.
Xavier AlvarezTexas Biomedical Research Institute, San Antonio, Texas, USA.
Smriti MehraTexas Biomedical Research Institute, San Antonio, Texas, USA.
Shabaana A KhaderDepartment of Microbiology, University of Chicago, Chicago, Illinois, USA.
Dhiraj K SinghTexas Biomedical Research Institute, San Antonio, Texas, USA.
Deepak KaushalTexas Biomedical Research Institute, San Antonio, Texas, USA.

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
Viral Testing CoreU42OD010442 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Deepak Kaushal, Kathryn Shelton · 2012 to 2026
$35.6M
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSISR01AI111914 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2015 to 2025
$11.1M
Immune Correlates of Protection from TBR01AI134240 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK · 2017 to 2022
$4.8M
SigH based attenuated, efficacious Mtb vaccines to protect against lethal TBR01AI138587 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI JAGANNATH, CHINNASWAMY, KAUSHAL, DEEPAK · 2018 to 2022
$4.4M
Mechanisms of efficient control of Mycobacterium tuberculosis in the lungs prior to granulomaR01AI184623 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Deepak Kaushal, Shabaana A. Khader · 2024 to 2026
$3.9M
Evaluating the safety, immunogenicity and efficacy of a robust attenuated Mtb vaccine in the setting of HIV co-infectionR01AI189313 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Deepak Kaushal · 2025 to 2026
$1.8M
Significant upgrade and expansion of the Southwest National Primate Research Center Pathology UnitS10OD028732 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI KAUSHAL, DEEPAK · 2020 to 2020
$489k
BD FACSymphonyS10OD028653 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI TURNER, JOANNE · 2020 to 2020
$463k
Dual Beckman Coulter DxH 690T and Beckman Coulter DxH 560 ALS10OD032443 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI TURNER, JOANNE · 2022 to 2022
$86k
NIAID NIH HHS R01 AI111914NIAID NIH HHS R01 AI134240NIAID NIH HHS R01 AI138587NIAID NIH HHS R01 AI184623NIAID NIH HHS R01 AI189313NIH HHS P51 OD011133NIH HHS S10 OD028653NIH HHS S10 OD028732NIH HHS S10 OD032443NIH HHS U42 OD010442
6 · The paper itself

Abstract

To radically diminish tuberculosis (TB) incidence and mortality by 2035, as set out by the WHO End TB Strategy, there is a desperate need for improved TB therapies and a more effective vaccine against the deadly pathogen Mycobacterium tuberculosis. Aerosol vaccination with the MtbΔsigH mutant protects 2 species of nonhuman primates against lethal TB challenge by invoking vastly superior T and B cell responses in the lungs through superior antigen presentation and interferon conditioning. Since the Geneva Consensus on essential steps toward the development of live mycobacterial vaccines recommends that live TB vaccines incorporate at least 2 independent gene knockouts, we have now generated several rationally designed, double-knockout (DKO) and triple-knockout (TKO) mutants in Mtb, each containing the ΔsigH deletion. Here, we report preclinical studies in the rhesus macaque model of aerosol infection and SIV/HIV coinfection, aimed at assessing the safety of these MtbΔsigH-based DKOs and TKOs. We found that most of these mutant strains were attenuated in both immunocompetent and SIV-coinfected macaques, and combinatorial infection with these generated strong cellular immune responses in the lung, akin to MtbΔsigH. Aerosol infection with these KO strains elicited inducible bronchus-associated lymphoid tissue, which is a correlate of protection from TB.

Indexed as

Mycobacterium tuberculosisTuberculosisTuberculosis VaccinesAnimalsDisease Models, AnimalFemaleHIV InfectionsLungMacaca mulattaMaleSimian Acquired Immunodeficiency SyndromeVaccines, AttenuatedTuberculosis VaccinesVaccines, AttenuatedInfectious diseaseMicrobiologyTuberculosisVaccines

Identifiers

PMID40875531
PMCPMC12513488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.